Cargando…

PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy

This study aimed to identify potential predictive factors for the survival of advanced lung adenocarcinoma patients undergoing pemetrexed maintenance therapy. 122 advanced lung adenocarcinoma patients who received pemetrexed maintenance therapy were retrospectively analyzed. Kaplan–Meier method with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Yi, Jiang, Lili, Yu, Min, Li, Yanying, Zhou, Xiaojuan, Wang, Yongsheng, Gong, Youling, Peng, Feng, Zhu, Jiang, Liu, Yongmei, Xu, Yong, Zhou, Lin, Lu, You, Huang, Meijuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7527332/ https://www.ncbi.nlm.nih.gov/pubmed/32999345 http://dx.doi.org/10.1038/s41598-020-73013-3

Ejemplares similares

Efficacy and safety of pemetrexed and nedaplatin followed by pemetrexed maintenance therapy in advanced lung adenocarcinoma
por: Lin, Zhong, et al.
Publicado: (2017)

A phase I study of the tyrosine kinase inhibitor anlotinib combined with platinum/pemetrexed-based chemotherapy in untreated nonsquamous non-small-cell lung cancer
por: Huang, Meijuan, et al.
Publicado: (2021)

Efficacy of epidermal growth factor receptor–tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports
por: Liu, Yongmei, et al.
Publicado: (2017)

PD-L1 expression indicates favorable prognosis for advanced lung adenocarcinoma patients treated with pemetrexed
por: Zhang, Pei, et al.
Publicado: (2017)

Changes of Brain Structure in Patients With Metastatic Non-Small Cell Lung Cancer After Long-Term Target Therapy With EGFR-TKI
por: Yang, Beisheng, et al.
Publicado: (2021)

Real‐world clinical analysis in 190 advanced NSCLC patients with uncommon EGFR mutations: A multi‐center study
por: Qin, Yi, et al.
Publicado: (2023)

Planning analysis for locally advanced lung cancer: dosimetric and efficiency comparisons between intensity-modulated radiotherapy (IMRT), single-arc/partial-arc volumetric modulated arc therapy (SA/PA-VMAT)
por: Jiang, Xiaoqin, et al.
Publicado: (2011)

Comparison of chemotherapy plus bevacizumab vs. chemotherapy alone as third-line treatment or beyond for advanced non-small cell lung cancer: A propensity score-matched analysis
por: Hu, Binbin, et al.
Publicado: (2018)

Efficacy and toxicity profile of maintenance pemetrexed in patients with stage IV adenocarcinoma lung in Indian population
por: Pankaj, Goyal, et al.
Publicado: (2016)

Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial?
por: Zou, Bingwen, et al.
Publicado: (2020)

Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score
por: Liu, Yongmei, et al.
Publicado: (2017)

Concurrent paclitaxel-based chemo-radiotherapy for post-surgical microscopic residual tumor at the bronchial margin (R(1) resection) in non-small-cell lung cancer
por: Zhou, Meixiang, et al.
Publicado: (2015)

Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis
por: Paik, Seung Sook, et al.
Publicado: (2018)

An overview of PROTACs: a promising drug discovery paradigm
por: Liu, Zi, et al.
Publicado: (2022)

Salvage concurrent radio-chemotherapy for post-operative local recurrence of squamous-cell esophageal cancer
por: Zhang, Jian, et al.
Publicado: (2012)

Stereotactic body radiation therapy for post-pulmonary lobectomy isolated lung metastasis of thoracic tumor: survival and side effects
por: Xiong, Weijie, et al.
Publicado: (2014)

Icotinib and pemetrexed in treatment of lung adenocarcinoma and the effects on prognostic survival rate of patients
por: Zhou, Xueheng, et al.
Publicado: (2019)

Rapid response to monotherapy with MEK inhibitor trametinib for a lung adenocarcinoma patient harboring primary SDN1-BRAF fusion: A case report and literature review
por: Yu, Yang, et al.
Publicado: (2022)

Significance of thymidylate synthase expression for resistance to pemetrexed in pulmonary adenocarcinoma
por: YANG, MIN, et al.
Publicado: (2014)

Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung
por: Jung, Minkyu, et al.
Publicado: (2013)

Safety and Efficacy of Pemetrexed in Maintenance Therapy of Non-Small Cell Lung Cancer
por: Velez, Michel, et al.
Publicado: (2012)

CBDCA + Pemetrexed + Bevacizumab and Its Maintenance Chemotherapy in a Case of Solitary Breast Metastasis from a Lung Adenocarcinoma Resistant to Gefitinib
por: Sato, Kazuhide, et al.
Publicado: (2012)

Paclitaxel and cisplatin combined with intensity-modulated radiotherapy for upper esophageal carcinoma
por: Tu, Lingli, et al.
Publicado: (2013)

Efficacy and safety of rh‐endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh‐endostatin plus pemetrexed maintenance in non‐small cell lung cancer: A retrospective comparison with standard chemotherapy
por: Zhou, Shengyu, et al.
Publicado: (2018)

Survival Benefit and Genetic Profile of Pemetrexed as Initial Chemotherapy in Selected Chinese Patients With Advanced Lung Adenocarcinoma
por: Guo, Long-Hua, et al.
Publicado: (2020)

Successful Treatment with Pemetrexed, Carboplatin, and Bevacizumab for Platinum-Resistant Adenocarcinoma of the Lung
por: Wada, Sae, et al.
Publicado: (2012)

Pemetrexed in maintenance treatment of advanced non-squamous non-small-cell lung cancer
por: Minami, Seigo, et al.
Publicado: (2015)

Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
por: YOKOI, TAKASHI, et al.
Publicado: (2014)

Clinical efficacy and safety evaluation of pemetrexed combined with radiotherapy in treatment of patients with lung adenocarcinoma brain metastasis
por: Zhang, Guoqiao, et al.
Publicado: (2019)

Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience
por: Lin, Liping, et al.
Publicado: (2016)

Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression
por: Cardona, Andrés Felipe, et al.
Publicado: (2016)

Sequentially administrated of pemetrexed with icotinib/erlotinib in lung adenocarcinoma cell lines in vitro
por: Feng, Xiuli, et al.
Publicado: (2017)

Adjuvant Therapeutic Modalities in Primary Small Cell Carcinoma of Esophagus Patients: A Retrospective Cohort Study of Multicenter Clinical Outcomes
por: Zou, Bingwen, et al.
Publicado: (2016)

Comparison of erlotinib and pemetrexed as second-/third-line treatment for lung adenocarcinoma patients with asymptomatic brain metastases
por: He, Yayi, et al.
Publicado: (2016)

Dosimetric comparison using different multileaf collimeters in intensity-modulated radiotherapy for upper thoracic esophageal cancer
por: Gong, Youling, et al.
Publicado: (2010)

Efficacy and safety of first-line pemetrexed plus carboplatin followed by single-agent pemetrexed maintenance in elderly Chinese patients with non-squamous non-small-cell lung cancer
por: Zhao, Xinmin, et al.
Publicado: (2017)

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
por: Tsutani, Yasuhiro, et al.
Publicado: (2018)

Predictors of long‐term outcomes in patients undergoing periodontal maintenance
por: Martinez‐Canut, Pedro, et al.
Publicado: (2017)

Pemetrexed induced pneumonitis
por: Dhakal, Binod, et al.
Publicado: (2011)

Pericardial irradiation dose may be strongly associated with grade 4 lymphopenia and affect prognosis in patients with locally advanced esophageal cancer receiving definitive concurrent chemoradiotherapy
por: Chen, Xianyan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_d2chfq45fds5c36kda18hsdiqi